NCT03749980Recruiting
MyVHL: Patient Natural History Study
Source: ClinicalTrials.gov · Last updated 26 Apr 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
MyVHL is a multi-patient database which helps researchers identify patterns across VHL patients. MyVHL provides you -and researchers -with more complete information about VHL, like how your lifestyle, medications, and other factors impact the disease and quality of life. These insights help you better understand the condition and help researchers know where to focus their efforts. Due to its rarity, there is less understanding of VHL and the factors that may have an impact. The data individuals provide in MyVHL helps researchers identify and uncover factors that may increase risk, inhibit or slow tumor growth, or lead to an effective cure.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 10000 (estimated)
- First submitted
- 30 May 2018
- Start date
- Jan 2012
- Primary completion date
- Dec 2028
- Lead sponsor
- Joshua Mann, MPH
- Diseases
- Kidney cancer, Childhood cancers
- NCT number
- NCT03749980
What you commit to
- Study type: Observational
- Planned participants: 10000
- From Jan 2012 to the primary completion date, Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- All patients with von Hippel-Lindau Disease (VHL)
Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| VHL Alliance Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.